Free tool
FAERS Monitor: Dysport
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125274 or its brand name (Dysport, Abobotulinumtoxina). Reports on generic versions are filed under their own applications.
Reports
12,740
Serious
7,124
56% of reports
Hospitalization
2,912
Death reported
1,978
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use4,935
- drug ineffective3,728
- headache1,650
- drug intolerance1,376
- product use in unapproved indication1,364
- nausea1,328
- migraine1,209
- dizziness1,180
- pain1,176
- hypoaesthesia1,160
- fatigue1,113
- asthenia1,089
- muscular weakness1,053
- paraesthesia984
- maternal exposure during pregnancy983
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 7 |
| 2005 | 7 |
| 2006 | 10 |
| 2007 | 35 |
| 2008 | 69 |
| 2009 | 87 |
| 2010 | 147 |
| 2011 | 179 |
| 2012 | 642 |
| 2013 | 75 |
| 2014 | 69 |
| 2015 | 85 |
| 2016 | 127 |
| 2017 | 876 |
| 2018 | 1,118 |
| 2019 | 631 |
| 2020 | 563 |
| 2021 | 967 |
| 2022 | 1,272 |
| 2023 | 1,463 |
| 2024 | 1,561 |
| 2025 | 1,713 |
| 2026 | 1,037 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,041,419 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug intoleranceSignal | 1,376 | 23.8 | 22.7 | 29,797 |
| migraineSignal | 1,209 | 21.2 | 20.1 | 23,017 |
| maternal exposure during pregnancySignal | 983 | 18.4 | 17.3 | 16,048 |
| muscular weaknessSignal | 1,053 | 15.4 | 14.6 | 14,139 |
| hypoaesthesiaSignal | 1,160 | 12.9 | 12.2 | 12,698 |
| paraesthesiaSignal | 984 | 10.4 | 9.8 | 8,346 |
| off label useSignal | 4,935 | 9.4 | 9.1 | 38,182 |
| product use in unapproved indicationSignal | 1,364 | 9.1 | 8.7 | 9,930 |
| astheniaSignal | 1,089 | 4.8 | 4.5 | 3,314 |
| drug ineffectiveSignal | 3,728 | 4.7 | 4.6 | 11,474 |
| headacheSignal | 1,650 | 4.4 | 4.2 | 4,379 |
| dizzinessSignal | 1,180 | 3.9 | 3.7 | 2,612 |
| painSignal | 1,176 | 3.2 | 3.0 | 1,788 |
| nauseaSignal | 1,328 | 2.8 | 2.6 | 1,560 |
| fatigueSignal | 1,113 | 2.4 | 2.2 | 905 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.